US-based biotechnology company PMV Pharmaceuticals, announced the appointment of Steven Holtzman, pharmaceutical company Biogen Idec’s executive vice president for corporate development, to its board of directors.
PMV Pharmaceuticals aims to harvest the biology of p53 and p53 pathway modulators for the treatment of cancer and other infectious human diseases. Based in California and Pennsylvania, the startup has received funding from venture capital firm InterWest Partners.
Holtzman said: “PMV Pharmaceuticals has assembled a world-class team. Now is the time to apply the knowledge accumulated over decades of p53 research into the discovery and development of life changing medicines. The era of big biology is upon us, and I expect PMV Pharma to be a major player in a new generation of medicines.”
David Mack, president and CEO of PMV Pharmaceuticals, added: “The addition of Steve Holtzman to our board provides us with important strategic insights as we look to develop our cancer and infectious disease therapeutics. Steve’s proven business and commercial expertise will be of great value as our product portfolio continues to mature.”
– Photo of Steven Holtzman courtesy of Biogen Idec